Mirum Pharmaceuticals, Inc.
MIRMDrugs in Pipeline
10
Phase 3 Programs
5
Upcoming Catalysts
2
Next Catalyst
Jun 15, 2026
13wMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
Maralixibat
Biliary Atresia
Cholic acid
Inborn Errors of Bile Acid Synthesis
Cholic Acids
Infantile Refsum's Disease
Blinded CDCA 250 mg TID
CTX
Brelovitug (BJT-778)
Chronic Hepatitis D
Ursodeoxycholic Acid
PBC
LUM001 (Maralixibat)
Alagille Syndrome
Volixibat
Primary Biliary Cholangitis
Low dose of MRM-3379
Fragile X Syndrome
LUM001
Alagille Syndrome
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Maralixibat | Phase 3 | Biliary Atresia | - | - |
Cholic acid | Phase 3 | Inborn Errors of Bile Acid Synthesis | - | - |
Cholic Acids | Phase 3 | Infantile Refsum's Disease | - | - |
Blinded CDCA 250 mg TID | Phase 3 | CTX | - | - |
Brelovitug (BJT-778) | Phase 3 | Chronic Hepatitis D | - | - |
Ursodeoxycholic Acid | Phase 2 | PBC | - | - |
LUM001 (Maralixibat) | Phase 2 | Alagille Syndrome | - | - |
Volixibat | Phase 2 | Primary Biliary Cholangitis | - | - |
Low dose of MRM-3379 | Phase 2 | Fragile X Syndrome | - | - |
LUM001 | Phase 2 | Alagille Syndrome | - | - |
Alagille Syndrome
3 drugs in this indication
Inborn Errors of Bile Acid Synthesis
1 drug in this indication
PBC
1 drug in this indication
Fragile X Syndrome
1 drug in this indication
Biliary Atresia
1 drug in this indication
Primary Biliary Cholangitis
1 drug in this indication
CTX
1 drug in this indication
Infantile Refsum's Disease
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)